KA vs. LIXT, ADIL, ENVB, LIPO, HOTH, FWBI, XBIO, YMTX, PCSA, and GNPX
Should you be buying Kineta stock or one of its competitors? The main competitors of Kineta include Lixte Biotechnology (LIXT), Adial Pharmaceuticals (ADIL), Enveric Biosciences (ENVB), Lipella Pharmaceuticals (LIPO), Hoth Therapeutics (HOTH), First Wave BioPharma (FWBI), Xenetic Biosciences (XBIO), Yumanity Therapeutics (YMTX), Processa Pharmaceuticals (PCSA), and Genprex (GNPX). These companies are all part of the "pharmaceutical preparations" industry.
Lixte Biotechnology (NASDAQ:LIXT) and Kineta (NASDAQ:KA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Kineta received 3 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
Lixte Biotechnology has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, Kineta has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
In the previous week, Kineta had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for Kineta and 1 mentions for Lixte Biotechnology. Kineta's average media sentiment score of 0.99 beat Lixte Biotechnology's score of 0.16 indicating that Lixte Biotechnology is being referred to more favorably in the media.
Lixte Biotechnology has higher earnings, but lower revenue than Kineta. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Kineta, indicating that it is currently the more affordable of the two stocks.
Kineta has a consensus target price of $8.00, suggesting a potential upside of 1,669.91%. Given Lixte Biotechnology's higher probable upside, analysts plainly believe Kineta is more favorable than Lixte Biotechnology.
Lixte Biotechnology's return on equity of -422.82% beat Kineta's return on equity.
5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 30.3% of Kineta shares are owned by institutional investors. 15.5% of Lixte Biotechnology shares are owned by insiders. Comparatively, 29.8% of Kineta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Kineta beats Lixte Biotechnology on 11 of the 14 factors compared between the two stocks.
Get Kineta News Delivered to You Automatically
Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
